In Section A, contributors will receive diverse doses and schedules of oral ABBV-744 pill to determine Protected dosing program. Extra members will be enrolled with the determined monotherapy dosign program. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 will probably be supplied as "add-on" therapy. In Segment C, https://abbv-744-clinical-trial-p36802.csublogs.com/38620435/indicators-on-clinical-trial-recruitment-for-abbv-744-study-you-should-know